DNA adducts, detected by [sup 32]P postlabelling, in human cholangiocarcinoma

Khan, S.A.; Carmichael, P.L.; Taylor-Robinson, S.D.; Habib, N.; Thomas, H.C.
April 2003
Gut;Apr2003, Vol. 52 Issue 4, p586
Academic Journal
Background: Reported mortality from intrahepatic cholangiocarcinoma (CCa) has risen steeply in the UK and other industrialised countries over the past 30 years, the cause of which has not been explained. DNA adduct formation is promutagenic and demonstrates exposure to a DNA damaging agent. It is a key step in chemically induced carcinogenesis. We hypothesise that the increase in CCa mortality is caused by a rise in a genotoxic environmental agent(s), causing cholangiocyte DNA damage. Aims: To investigate and compare tumour and tumour adjacent CCa tissue, and non-cancer control bile duct tissue, for DNA adducts as a biomarker of genotoxin exposure. Methods: DNA from 32 intrahepatic CCa patients (and in 28 cases DNA from adjacent non-tumour tissue) and from biliary ducts of seven non-cancer patients were investigated for the presence of DNA adducts using the nuclease P1 method of [sup 32]P postlabelling. DNA adduct levels (number of adducts/10[sup 8] nucleotides) were quantified. Results: There was no significant difference in relative adduct labellings (RALs) between tumour adjacent DNA (median 8.6, range 1.2-51.6) and CCa DNA (7.2, 1.8-48.4). However, RALs were significantly higher in DNA from cancer patients (tumour adjacent and CCa DNA) compared with noncancer patient DNA (2.9, 0.6-11.5; p=0.032, two tailed Mann-Whitney U test). Different adduct patterns were also seen in CCa compared with non-cancer patients. Conclusion: Quantitative and qualitative differences in adducts between cancer and non-cancer patients support the hypothesis that genotoxins may play a role in the development of intrahepatic CCa.


Related Articles

  • Significance of mucin expression in pancreatobiliary neoplasms. Yonezawa, Suguru; Higashi, Michiyo; Yamada, Norishige; Yokoyama, Seiya; Goto, Masamichi // Journal of Hepato -- Biliary -- Pancreatic Sciences;Mar2010, Vol. 17 Issue 2, p108 

    Mucins are high molecular weight glycoproteins that play important roles in carcinogenesis and tumor invasion. We have described, for the first time, that pancreatic ductal adenocarcinomas (PDACs) with an aggressive behavior and a poor outcome expressed MUC1 (pan-epithelial membrane-associated...

  • Chronic typhoid infection and the risk of biliary tract cancer and stones in Shanghai, China. Safaeian, Mahboobeh; Yu-Tang Gao; Sakoda, Lori C.; Quraishi, Sabah M.; Rashid, Asif; Bing-Shen Wang; Jinbo Chen; Pruckler, James; Mintz, Eric; Hsing, Ann W. // Infectious Agents & Cancer;2011, Vol. 6 Issue 1, p6 

    Previous studies have shown a positive association between chronic typhoid carriage and biliary cancers. We compared serum Salmonella enterica serovar Typhi antibody titers between biliary tract cancer cases, biliary stone cases without evidence of cancer, and healthy subjects in a large...

  • Biliary tract carcinoma: clinical perspectives on molecular targeting strategies for therapeutic options. Shoda, Junichi; Ishige, Kazunori; Sugiyama, Hiroaki; Kawamoto, Toru // Journal of Hepato -- Biliary -- Pancreatic Sciences;Jul2012, Vol. 19 Issue 4, p342 

    Biliary tract carcinoma (BTC) is a lethal malignancy. This lethality is essentially attributed to both slow carcinogenesis occurring under complex pathological circumstances and to the asymptomatic growth of BTC infiltrating the surrounding structures by varying routes. The disease is therefore...

  • Reply to Classification of biliary tract cancer (BTC): evaluation of all entities. Randi, G.; Malvezzi, M.; Levi, F.; Ferlay, J.; Negri, E.; Franceschi, S.; Vecchia, C. La // Annals of Oncology;Jun2009, Vol. 20 Issue 6, p1149 

    A review of the article "Classification of Biliary Tract Cancer (BTC): Evaluation of All Entities," by G. Tonini, M.E. Fratto, and B. Vincenzi, which appeared in this issue is presented.

  • Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract. Miller, George; Socci, Nicholas D.; Dhall, Deepti; D'Angelica, Michael; DeMatteo, Ronald P.; Allen, Peter J.; Singh, Bhuvanesh; Yuman Fong; Blumgart, Leslie H.; Klimstra, David S.; Jarnagin, William R. // Journal of Experimental & Clinical Cancer Research (17569966);2009, Vol. 28, p1 

    Background: The pathogenesis of biliary cancers is ill-defined. This study investigates changes in gene expression and copy number in biliary cancers and correlates these changes with anatomical site of origin, histopathology and outcome. Methods: We performed gene expression and CGH analysis on...

  • Triple carcinomas of the biliary tract associated with congenital choledochal dilatation and pancreaticobiliary maljunction. Okamura, Kazunori; Hayakawa, Hiroki; Kuze, Masaya; Takahashi, Hiroaki; Kosaka, Atsushi; Mizumoto, Ryuji; Katsuta, Koji // Journal of Gastroenterology;2000, Vol. 35 Issue 6, p465 

    Abstract: We report a rare case of triple carcinomas of the biliary tract associated with congenital choledochal dilatation (CCD) and pancreaticobiliary maljunction (PBM). The patient was a 58-year-old Japanese man who complained of epigastralgia. Ultrasonography and computed tomography revealed...

  • Usefulness of p53 gene mutations in the supernatant of bile for diagnosis of biliary tract carcinoma: comparison with K-ras mutation. Wang, Ying; Yamaguchi, Yasushi; Watanabe, Hiroyuki; Ohtsubo, Koushiro; Wakabayashi, Tokio; Sawabu, Norio // Journal of Gastroenterology;2002, Vol. 37 Issue 10, p831 

    Background. The sensitivity of bile cytology for the diagnosis of biliary tract carcinoma (BTCa) is still low. In addition, the incidence of detection of genetic mutations in the bile of BTCa is not satisfactory yet. To improve the molecular diagnosis of BTCa, we analyzed p53 and K-ras mutations...

  • Hepatic peribiliary cysts: clinically harmless disease with potential risk due to gradual increase in size and number. Kudo, Masatoshi // Journal of Gastroenterology;2001, Vol. 36 Issue 4, p286 

    Editorial. Provides information on hepatic peribiliary cysts. Description of the cysts; Risk factors of peribiliary cysts; Conditions associated with the disease; Clinical presentation of hepatic peribiliary cysts.

  • Cetuximab, gemcitabine, capecitabine combination active in biliary tract cancer.  // Hem/Onc Today;1/10/2014, Vol. 15 Issue 1, p9 

    The article reports that according to the results of an exploratory phase two trial, patients with inoperable biliary tract cancer appeared to have tolerated well the combination of cetuximab, gemcitabine and capecitabine, which also showed encouraging activity.


Read the Article


Sign out of this library

Other Topics